Daewoong's P-CAB Contender Holds Up Well At Phase III
Non-Inferior To Esomeprazole
South Korean firm presents encouraging Phase III data for its novel P-CAB drug fexuprazan at Digestive Disease Week and hopes the results will accelerate entry into global markets.
You may also be interested in...
Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.